Exiqon and Asuragen Sign Agreement for Real-Time PCR Services
News Jun 11, 2013
The Asuragen Genomic Services Division provides a comprehensive range of nucleic acid-based services from biomarker discovery to development of companion diagnostics (isolation/preparation from multiple sample types, genomic profiling, miRNA/mRNA expression profiling, assay development and validation, CLIA-based clinical trial testing, bioinformatics, and regulatory services).
LNA™-based microRNA real-time PCR profiling holds great promise as a non-invasive way to discover important new biomarkers for a wide range of diseases and biological processes. Exiqon’s microRNA real-time PCR system combines a Universal RT reaction with LNA™-enhanced PCR primers, which results in unmatched sensitivity and specificity for all sample types.
”Exiqon’s high quality microRNA PCR products allow us to further expand our service offerings to meet the needs of our pharmaceutical and diagnostic partners”, said Carol Berry, Sr. Vice President & GM of Asuragen Genomic Services Division.
In a comment, Sr. VP Sales & Marketing, Henrik Pfundheller of Exiqon said: “We are honored and excited to support Asuragen on the discovery of novel microRNA biomarkers” and added: “Asuragen are experts in their own right in the field of microRNA and this is a great opportunity for us to expand our presence in the U.S. market.”
LogicTRN Model Illuminates Regulatory Gene FrameworkNews
A newly devised algorithm called LogicTRN has the potential to unravel the complexities of genetic regulation, authors say.READ MORE
Genetic Variations in the Lungs Identify COPD RiskNews
Developmental genetic variations in the anatomy of the lung could indicate people at risk of COPD later in life, a study suggests.READ MORE